A novel coronavirus (2019-nCoV) has been featured on every headline this past week as the WHO declares the outbreak a global public-health emergency. The 2019-nCoV causes illness ranging from the common cold to mores severe diseases such as Severe Acute Respiratory Syndrome (SARS), which can spread from person-to-person. The CDC believes that symptoms may appear in as few as 2 days or as long as 14 days after exposure. Common symptoms include a fever, cough, shortness of breath and breathing difficulties. In more severe cases, infection can cause pneumonia, severe respiratory issues, kidney failure and even death.

The 2019-nCoV was first identified in Wuhan, China on December 31, 2019.  It quickly traveled around the world and the United States reported its first case on January 21, 2020. Since the break out (as of January 30th), over 7,800 people have been infected and 170 people have died, according to statistics. However, scientists believe that the real number is likely higher.

There is currently no vaccine to protect against the 2019-nCoV, nor any specific antiviral treatment. The best way to prevent the infection is to avoid being exposed to the virus. Government scientists in China, the United States and Australia, as well as those working at Johnson & Johnson, Moderna Therapeutics and Inovio Pharmaceuticals are all working quickly to develop a new vaccine. According to the New York Times, “The hunt began January 10th, when Chinese scientists posted the genetic make-up of the virus on a public database. The next morning, researchers at the National Institute of Health’s Vaccine Research Center in Maryland went to work. Within hours, they had pinpointed the parts of the genetic code that could be used to make a vaccine.”

Despite the quick response from several teams of scientist around the world, creating a vaccine for the 2019-nCoV can be a very long and expensive process.  The first step is to identify the natural or synthetic antigens that might help prevent it. Then scientist will study how it interacts on a cellular level. After they are able to identify that it will be safe and effective for humans, clinical trials begin for Phases 1 – 3 research.  After a successful Phase 3 trial (which could take up to several months or years), the manufacturer will submit for a license through the FDA, and it will be available for the general public. The only way to create a vaccine and determine if it is effective is to perform research studies at sites similar to Rochester Clinical Research, and provide the data to confirm that a vaccine is safe and effective. If you would like to help advance medicine and change lives and join a vaccine research study, please see below what we have available . Be sure to check back often, as we have new studies starting all the time.

Chikungunya Vaccine Study

Rochester Clinical Research is participating in a study evaluating the immune response of a single dose of the Chikungunya vaccine in healthy adolescents between the ages of 12 and 17 years old. The study will last approximately 6 months with 7 visits to our office. Compensation is available for up to $650 for time and travel, for those who qualify.

View Trial Details
Ages 12 – 17
Compensation* $650
Study Topics Chikungunya Virus

*Compensation for time and travel may be available to those who qualify.

Featured

Dengue Fever Vaccine Study

Dengue fever is a virus that is carried by mosquitoes, usually in subtropical and tropical climates. Symptoms can range from either being mild or severe. The virus only lasts about a week, but if left untreated it could turn into severe symptoms. We are conducting a phase 2 study of a vaccine for people ages 18-50 years old to test the safety and efficiency of different doses given. It’s a one-year-long trial with 8 visits to the office.

View Trial Details
Ages 18 – 50
Compensation* $120 per visit
Study Topics Dengue Fever

*Compensation for time and travel may be available to those who qualify.

Featured

Chikungunya Vaccine Study

Chikungunya is a virus that can be spread through mosquito bites similar to other mosquito-spread illnesses like Zika, malaria, dengue, and West Nile Virus. RCR is conducting a study to test the effectiveness of a phase 3 vaccine to prevent Chikungunya in people who are 65 or older. The study will be 7 months long and consists of 5 office visits and 2 phone call appointments.

View Trial Details
Ages 65+
Compensation* $900
Study Topics Chikungunya Virus

*Compensation for time and travel may be available to those who qualify.

Featured

Dengue Fever Vaccine Study

Dengue fever is a virus that is carried by mosquitoes, usually in subtropical and tropical climates. There currently isn’t a vaccine for adults, only children who are between the ages of 9-16. We are conducting a phase 2 study of a vaccine for people ages 18-50 years old to test the safety and efficiency of different doses given. It’s a one-year-long trial with 8 visits to the office.

View Trial Details
Ages 18 – 50
Compensation* $120 per visit
Study Topics Dengue Fever

*Compensation for time and travel may be available to those who qualify.

Featured

Lyme Disease Vaccine Study

There currently isn’t a vaccine out there to protect against Lyme disease. RCR is conducting a study testing the safety and efficacy of a phase 3 vaccine to help prevent Lyme disease. This study will last approximately 3 years with 7 visits to our RCR office along with 1 phone call appointment. We are seeking individuals who are 5 years and older to participate in the study.

View Trial Details
Ages 5+
Compensation* $1,090
Study Topics Lyme Disease Vaccine

*Compensation for time and travel may be available to those who qualify.

Featured

Flu Vaccine Study

Rochester Clinical Research is now seeking volunteers between the ages of 65 and 85 years old for an influenza vaccine study. The purpose of this research study is to evaluate the safety and effectiveness of an investigational influenza vaccine versus a currently approved influenza vaccine.

View Trial Details
Ages 65 – 85
Compensation* $625
Study Topics Flu Vaccine

*Compensation for time and travel may be available to those who qualify.

COVID booster plus Influenza Vaccine Study

Rochester Clinical Research is now enrolling volunteers between the ages of 18 and 75 years old for an investigational COVID vaccine booster plus flu vaccine study.

View Trial Details
Ages 18 – 75
Study Topics Vaccine

Pneumococcal Vaccine Study

Rochester Clinical Research is now seeking volunteers between the ages of 50 and 64 years old for a research study to evaluate the safety and efficacy of an investigational Pneumococcal vaccine.

View Trial Details
Ages 50 – 64
Compensation* $937.50
Study Topics Vaccine

*Compensation for time and travel may be available to those who qualify.

COVID-19 Vaccine Booster Study Interest List

If you are interested in continuing to advance our protection from COVID-19 and would like to potentially participate in a future booster study designed to protect against specific variants, submit your information to be added to our COVID-19 Vaccine Booster Study interest list.

View Trial Details

COVID-19 Vaccine

Rochester Clinical Research is seeking volunteers over the age of 18 for a COVID-19 vaccine study to potentially protect against specific variants of COVID-19.

View Trial Details
Ages 18 – 85
Study Topics Vaccine

COVID booster plus Pneumococcal Vaccine Study

Rochester Clinical Research is seeking volunteers 50 years old and up for a study to evaluate the safety and effectiveness of a combination pneumococcal and COVID vaccine.

View Trial Details
Ages 50+
Study Topics Vaccine

Chikungunya Vaccine

Rochester Clinical Research is seeking volunteers between 12 to 17 years old for a study to evaluate the safety and effectiveness of a Chikungunya Vaccine in healthy adults.

View Trial Details
Ages 12 – 17
Compensation* $650
Study Topics Vaccine

*Compensation for time and travel may be available to those who qualify.

COVID Vaccine Booster Plus Flu Vaccine

Rochester Clinical Research is seeking volunteers over the age of 18 for a clinical trial that will be investigating the safety and effectiveness of a COVID-19 vaccine booster in conjunction with an influenza vaccine.

View Trial Details
Ages 18+
Study Topics Vaccine

COVID-19 Vaccine Booster

Rochester Clinical Research is seeking volunteers between the ages of 18-59 for a study to evaluate the safety and effectiveness of a COVID-19 vaccine booster.

View Trial Details
Ages 18
Study Topics Vaccine
Featured

CMV Vaccine

Rochester Clinical Research is currently seeking born-female volunteers between the ages of 16 and 40 years old to participate in a CMV vaccine study. The purpose of this study is to find a safe and effective vaccine against Cytomegalovirus.

View Trial Details
Ages 16 – 40
Gender For female patients only
Study Topics Vaccine

RSV Vaccine Study

If you are interested in helping find a vaccine to prevent RSV, and want to join a future RSV trial at RCR join our interest list!

View Trial Details
Study Topics Vaccine

Yellow Fever Vaccine

Rochester Clinical Research is currently seeking volunteers between the ages of 12 and 60 years old to participate in a Yellow Fever Vaccine study. The purpose of this study is to assess the immune response of the investigational vaccine as compared to the currently approved Yellow Fever vaccine.

View Trial Details
Ages 12 – 60
Compensation* $875
Study Topics Vaccine

*Compensation for time and travel may be available to those who qualify.

RSV Vaccine Study

RCR is currently seeking the help of volunteers over the age of 60 to participate in a study looking at the effectiveness of a vaccine for RSV.

View Trial Details
Ages 60+
Study Topics Vaccine

COVID-19 Vaccine Trial

Rochester Clinical Research is currently seeking volunteers over the age of 18 years old for a COVID-19 Vaccine research study.

View Trial Details
Ages 18+
Compensation* $1,200-$1,500
Study Topics COVID-19 Vaccine

*Compensation for time and travel may be available to those who qualify.